Spero Therapeutics, Inc.(SPRO)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,690 of 2,860 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Dilution Risk
SPRO Stock Analysis & AI Quality Score
AI stock analysis and institutional research for Spero Therapeutics, Inc. (SPRO), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores SPRO at 19.5/100 on a 32-signal composite quality model, placing it at rank #2,690 of 2,860 stocks — the bottom half of the AI-ranked universe. SPRO scores in the top quartile across free cash flow (99.9). Areas of concern include profitability (0.1) and revenue growth (0.2), which score below median versus the broader universe. Shareholder dilution risk is elevated at 22.3/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Spero Therapeutics, Inc. reports quarterly revenue of $258.0K, net income of $-7.2M, free cash flow of $15.9M. Top institutional holders of SPRO by reported 13-F value include GSK plc, PFIZER, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. SPRO trades on the Nasdaq exchange and files with the SEC under CIK 1701108. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate SPRO daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Spero Therapeutics, Inc. directly from SEC EDGAR. Spero Therapeutics, Inc.'s 13F Pro composite quality score has ranged between 3 and 44 since 2021, currently 19.5 — a stable long-term trajectory across 30 quarterly and live scoring snapshots.
Revenue
Q1 2026
$258.0K
Net Income
Q1 2026
$-7.2M
Free Cash Flow
Q1 2026
$15.9M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · Pro+Revenue
+94.0% YoYNet Income
Operating Income
+150.9% YoYEPS (Diluted)
+135.0% YoYTotal Assets
+46.1% YoYOp. Cash Flow
-326.8% YoY| Metric | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2017 | FY 2015 |
|---|---|---|---|---|---|---|
| Revenue | $103.8M +94.0% | $53.5M +193.1% | $18.3M +95.7% | $9.3M +371.5% | $2.0M | — |
| Net Income | $22.8M | — | $-89.8M -14.7% | $-78.3M -102.1% | $-38.7M -281.6% | $-10.2M |
| Operating Income | $21.5M +150.9% | $-42.2M +52.0% | $-88.0M -11.2% | $-79.1M -89.6% | $-41.7M -213.1% | $-13.3M |
| EPS (Diluted) | $0.43 +135.0% | $-1.23 +57.7% | $-2.91 | — | — | — |
| Total Assets | $182.4M +46.1% | $124.8M -27.0% | $171.1M +11.5% | $153.5M +64.2% | $93.5M | — |
| Operating Cash Flow | $-33.0M -326.8% | $-7.7M +88.0% | $-64.3M +25.1% | $-85.9M -119.6% | $-39.1M | — |
Track SPRO with AI-powered research
10 AI analysts debate this stock daily. Free to start.
Available Research
13F Pro tracks comprehensive data for Spero Therapeutics, Inc. including:
Top Institutional Holders of SPRO
GSK plc
$21.5M9,190,606 shPFIZER INC
$5.5M2,362,348 shVANGUARD CAPITAL MANAGEMENT LLC
$4.2M1,799,880 shRENAISSANCE TECHNOLOGIES LLC
$2.8M1,189,235 shAlphabet Inc.
$2.1M889,979 shTWO SIGMA INVESTMENTS, LP
$2.1M885,631 shGEODE CAPITAL MANAGEMENT, LLC
$1.2M519,922 shBlackRock, Inc.
$1.0M433,202 shAnson Funds Management LP
$987.4K421,956 shCITADEL ADVISORS LLC
$880.9K376,458 sh
| Fund | Value | Shares |
|---|---|---|
| GSK plc | $21.5M | 9,190,606 |
| PFIZER INC | $5.5M | 2,362,348 |
| VANGUARD CAPITAL MANAGEMENT LLC | $4.2M | 1,799,880 |
| RENAISSANCE TECHNOLOGIES LLC | $2.8M | 1,189,235 |
| Alphabet Inc. | $2.1M | 889,979 |
| TWO SIGMA INVESTMENTS, LP | $2.1M | 885,631 |
| GEODE CAPITAL MANAGEMENT, LLC | $1.2M | 519,922 |
| BlackRock, Inc. | $1.0M | 433,202 |
| Anson Funds Management LP | $987.4K | 421,956 |
| CITADEL ADVISORS LLC | $880.9K | 376,458 |
More Healthcare Companies
View all Healthcare →Unlock Full Research for SPRO
Get detailed financial analysis, insider activity, institutional flows, AI-powered debates, and quality rankings for Spero Therapeutics, Inc. and 2,800+ other companies.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is SPRO a good stock to buy?
13F Pro's AI-powered analysis of Spero Therapeutics, Inc. (SPRO) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for SPRO are available on the SPRO stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own SPRO?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling SPRO. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Spero Therapeutics, Inc.'s investment landscape.